Organization · Venture Capital
SYNthesis BioVentures
SYNthesis BioVentures is an early-stage biotech venture capital fund based in Parkville, Victoria, Australia, focusing on therapeutics from discovery through preclinical proof of concept and IND-enabling studies.
Overview
What SYNthesis BioVentures does
What SYNthesis BioVentures is
SYNthesis BioVentures is an early-stage biotech venture capital fund based in Parkville, Victoria, Australia, focusing on therapeutics from discovery through preclinical proof of concept and IND-enabling studies.
How it participates in the startup ecosystem
The current public profile supports funder and publisher capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2022
- Approximate age
- About 4 years
- Structured capabilities
- Funder · Publisher
- Last reviewed
- April 23, 2026
Official channels
Find SYNthesis BioVentures elsewhere
Open the official website or a supported primary organization account.
Capability profile
SYNthesis BioVentures as a funder
Investment thesis
SYNthesis BioVentures focuses on early stage therapeutics, investing in projects from discovery through preclinical proof of concept and IND enabling studies.
Focus narrative
SYNthesis BioVentures invests in therapeutics across various modalities, focusing on small molecules, biologics, and cell and gene therapies. Their investment strategy is tiered, with investments ranging from A$1 million for early stage projects to A$5 million for late preclinical and early clinical programs. The fund is agnostic regarding modality and indication, allowing for a broad approach to addressing medical needs.
Value beyond capital
SYNthesis BioVentures adds value to its portfolio companies through its deep scientific expertise and industry connections. The team, led by experienced professionals, can effectively evaluate and support preclinical assets, providing guidance and resources that generalist VCs may lack. Additionally, partnerships with leading research institutions enhance the fund's access to proprietary intellectual property and innovative therapeutic developments.
Terms and economics
- Typical check
- $1,000,000–$5,000,000
- Sweet spot
- $3,000,000
Focus and fit
- Stages
- Pre-seed · Seed · Seed+
- Regions
- Global
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 4
Portfolio context
Notable portfolio companies include: Aculeus Therapeutics: Developing small molecule drugs to modulate the immune system for pediatric cancers. Catalyst Therapeutics: Engaged in the development of novel drug candidates in collaboration with the Walter and Eliza Hall Institute of Medical Research. Anaxis Pharma: Focused on a novel treatment for inflammatory diseases, with first-in-human trials targeted for 2025. Skin2Neuron: Specializes in therapies for Alzheimer's and other neurodegenerative disorders, with clinical data expected in the coming years. Qubigen: An AI-based platform for drug discovery.
Capability profile
SYNthesis BioVentures as a publisher
Editorial focus
SYNthesis BioVentures is dedicated to investing in early stage therapeutics, specifically targeting small molecule therapeutics, biologics, and cell and gene therapies that address significant unmet medical needs. Their investment strategy spans from discovery through preclinical proof of concept and IND-enabling studies, with a structured approach to funding projects at various stages of development.
Audience value
SYNthesis BioVentures offers a unique advantage with its scientific depth and expertise in evaluating preclinical assets, which allows them to identify promising therapeutic opportunities that may be overlooked by generalist venture capitalists.
Format and cadence
- Content formats
- newsletter
- Primary platform
- Website
Availability
- Guest pitch state
- Not currently accepting
Audience and focus
- Audience
- Investors
- Sectors
- Biotech & Life Sciences
- Regions
- Oceania
Flagship work and coverage
Flagship properties
SYNthesis BioVentures publishes a series of newsletters that detail their investments and updates, including notable investments in companies such as Anaxis Pharma, Aculeus Therapeutics, Skin2Neuron, and Qubigen.
Common questions
What to know about SYNthesis BioVentures
Upseed classifies SYNthesis BioVentures under the Venture Capital organization type. Its current public profile includes funder and publisher capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 23, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.